A Clinical Stage Biopharmaceutical Company Built on Strong Partnerships and Strategic Alliances

Spero Therapeutics is actively pursing collaborations with non-commercial organizations for scientific expertise and funding support. As a growing clinical stage biopharmaceutical company, we’re currently receiving funding support from the following:

• U.S. National Institute of Allergy and Infectious Diseases (NIAID);
• U.S. Department of Defense (DoD);
• Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a public-private partnership funded by the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services.

We intend to continue collaborating with government agencies and non-profit foundations to support the development of our product candidates.

Spero Therapeutics welcomes inquiries regarding potential opportunities for collaboration across discovery, development and commercialization.

For more information about partnership opportunities, contact us.